(Q38130469)

29 August 2017

Multidisciplinary approaches to intrahepatic cholangiocarcinoma (English)

1 reference

29 August 2017

0 references

6

Timothy M Pawlik

1 reference

29 August 2017

1

Shishir K Maithel

1 reference

29 August 2017

T Clark Gamblin

2

1 reference

29 August 2017

Ihab Kamel

series ordinal

3

1 reference

29 August 2017

Celia Pamela Corona-Villalobos

series ordinal

4

1 reference

29 August 2017

Melanie Thomas

series ordinal

5

1 reference

29 August 2017

language of work or name

English

0 references

publication date

20 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

119

1 reference

29 August 2017

22

1 reference

29 August 2017

3929-3942

1 reference

Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans

29 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Cholangiocarcinoma: modern advances in understanding a deadly old disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Worldwide trends in mortality from biliary tract malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Cholangiocarcinomas can originate from hepatocytes in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

The role of infection by Opisthorchis viverrini, hepatitis B virus, and aflatoxin exposure in the etiology of liver cancer in Thailand. A correlation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Hemodynamics of intrahepatic cholangiocarcinoma: evaluation with single-level dynamic CT during hepatic arteriography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Intrahepatic cholangiocarcinoma: macroscopic type and stage classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Cholangiocarcinoma: pictorial essay of CT and cholangiographic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Usefulness of 18 F-FDG PET in intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

A proposed staging system for intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Management and extent of resection for intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Recurrence after operative management of intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Recurrence after surgical resection of intrahepatic cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Clinical diagnosis and staging of cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Phase II study of erlotinib in patients with advanced biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Leptin enhances cholangiocarcinoma cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Role of chemotherapy in treatments for biliary tract cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Genetic profiling of intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Newer Angiographic Observations in Cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Combined hepatocellular and cholangiocarcinoma of the liver: sonography, CT, angiography, and iodized-oil CT with pathologic correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Regional and systemic chemotherapy for primary hepatobiliary cancers and for colorectal cancer metastatic to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

The role of the gamma knife in the treatment of malignant primary and metastatic brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Adequate Lymph Node Assessment for Extrahepatic Bile Duct Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Cholangiolocellular carcinoma of the liver: CT and MR findings

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Magnetic resonance imaging of cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Discordance between conventional and detailed lymph node analysis in resected biliary carcinoma at or above the cystic duct: are we understaging patients?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Periostin activates integrin α5β1 through a PI3K/AKT‑dependent pathway in invasion of cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Stereotactic High Dose Fraction Radiation Therapy of Extracranial Tumors Using An Accelerator: Clinical experience of the first thirty-one patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28312

7 January 2021

Identifiers

DOI

10.1002/CNCR.28312

1 reference

29 August 2017

1 reference